EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische StudieOpen Access · CC BY 4.0

Evaluation of an artificial intelligence-based decision support for the detection of cutaneous melanoma in primary care: a prospective real-life clinical trial

Panagiotis Papachristou iD, My Söderholm, Jon Pallon, Marina Taloyan iD, Sam Polesie iD, John Paoli iD, Chris D Anderson iD, Magnus Falk iD

British Journal of Dermatology · 2024

DOI: 10.1093/bjd/ljae021 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift British Journal of Dermatology, 2024. Verfasst von Panagiotis Papachristou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Family Medicine and Primary Care, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Primary Health Care, Dermoscopy. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: grants from Region Östergötland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Use of artificial intelligence (AI), or machine learning, to assess dermoscopic images of skin lesions to detect melanoma has, in several retrospective studies, shown high levels of diagnostic accuracy on par with – or even outperforming – experienced dermatologists. However, the enthusiasm around these algorithms has not yet been matched by prospective clinical trials performed in authentic clinical settings. In several European countries, including Sweden, the initial clinical assessment of suspected skin cancer is principally conducted in the primary healthcare setting by primary care physicians, with or without access to teledermoscopic support from dermatology clinics.

Objectives

To determine the diagnostic performance of an AI-based clinical decision support tool for cutaneous melanoma detection, operated by a smartphone application (app), when used prospectively by primary care physicians to assess skin lesions of concern due to some degree of melanoma suspicion.

Methods

This prospective multicentre clinical trial was conducted at 36 primary care centres in Sweden. Physicians used the smartphone app on skin lesions of concern by photographing them dermoscopically, which resulted in a dichotomous decision support text regarding evidence for melanoma. Regardless of the app outcome, all lesions underwent standard diagnostic procedures (surgical excision or referral to a dermatologist). After investigations were complete, lesion diagnoses were collected from the patients’ medical records and compared with the app’s outcome and other lesion data.

Results

In total, 253 lesions of concern in 228 patients were included, of which 21 proved to be melanomas, with 11 thin invasive melanomas and 10 melanomas in situ. The app’s accuracy in identifying melanomas was reflected in an area under the receiver operating characteristic (AUROC) curve of 0.960 [95% confidence interval (CI) 0.928–0.980], corresponding to a maximum sensitivity and specificity of 95.2% and 84.5%, respectively. For invasive melanomas alone, the AUROC was 0.988 (95% CI 0.965–0.997), corresponding to a maximum sensitivity and specificity of 100% and 92.6%, respectively.

Conclusions

The clinical decision support tool evaluated in this investigation showed high diagnostic accuracy when used prospectively in primary care patients, which could add significant clinical value for primary care physicians assessing skin lesions for melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsPrimary Health CareDermoscopyArtificial IntelligenceSmartphoneMobile ApplicationsHumansProspective StudiesFemaleMaleMiddle AgedAgedAdultDecision Support Systems, ClinicalSwedenSensitivity and Specificity

Autor:innen und Institutionen

  • Division of Family Medicine and Primary Care, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
  • Atrium Healthcare Centre, Region Stockholm, Sweden.
  • Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
  • Ekholmen Primary Healthcare Centre, Region Östergötland, Linköping, Sweden.
  • Department of Clinical Sciences in Malmö, Family Medicine, Lund University, Malmö, Sweden.
  • Department of Research and Development, Region Kronoberg, Växjö, Sweden.

ORCID-Profile: Panagiotis Papachristou, Marina Taloyan, Sam Polesie, John Paoli, Chris D Anderson, Magnus Falk

Förderung

  • grants from Region Östergötland

Zitieren

APA

Papachristou, P., Söderholm, M., Pallon, J., Taloyan, M., Polesie, S., Paoli, J., Anderson, C. D., & Falk, M. (2024). Evaluation of an artificial intelligence-based decision support for the detection of cutaneous melanoma in primary care: a prospective real-life clinical trial. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljae021

Vancouver

Papachristou P, Söderholm M, Pallon J, Taloyan M, Polesie S, Paoli J, et al. Evaluation of an artificial intelligence-based decision support for the detection of cutaneous melanoma in primary care: a prospective real-life clinical trial. British Journal of Dermatology. 2024. doi:10.1093/bjd/ljae021

BibTeX
@article{Papachristou2024,
  author = {Papachristou, Panagiotis and Söderholm, My and Pallon, Jon and Taloyan, Marina and Polesie, Sam and Paoli, John and Anderson, Chris D and Falk, Magnus},
  title = {Evaluation of an artificial intelligence-based decision support for the detection of cutaneous melanoma in primary care: a prospective real-life clinical trial},
  journal = {British Journal of Dermatology},
  year = {2024},
  doi = {10.1093/bjd/ljae021}
}
Kostenlos starten →